- Home
- AQB vs LIPO Comparison
AQB vs LIPO Comparison
Compare AQB & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- LIPO
- Stock Information
- Founded
- AQB 1991
- LIPO 2005
- Country
- AQB United States
- LIPO United States
- Employees
- AQB N/A
- LIPO N/A
- Industry
- AQB
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- LIPO Health Care
- Exchange
- AQB Nasdaq
- LIPO Nasdaq
- Market Cap
- AQB 2.9M
- LIPO 3.1M
- IPO Year
- AQB N/A
- LIPO 2022
- Fundamental
- Price
- AQB $0.62
- LIPO $2.27
- Analyst Decision
- AQB Hold
- LIPO Strong Buy
- Analyst Count
- AQB 2
- LIPO 1
- Target Price
- AQB N/A
- LIPO $16.00
- AVG Volume (30 Days)
- AQB 30.8K
- LIPO 2.2M
- Earning Date
- AQB 03-31-2025
- LIPO 05-08-2025
- Dividend Yield
- AQB N/A
- LIPO N/A
- EPS Growth
- AQB N/A
- LIPO N/A
- EPS
- AQB N/A
- LIPO N/A
- Revenue
- AQB $1,258,512.00
- LIPO $483,533.00
- Revenue This Year
- AQB N/A
- LIPO N/A
- Revenue Next Year
- AQB $43.65
- LIPO N/A
- P/E Ratio
- AQB N/A
- LIPO N/A
- Revenue Growth
- AQB N/A
- LIPO 0.78
- 52 Week Low
- AQB $0.47
- LIPO $2.02
- 52 Week High
- AQB $2.31
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- AQB 37.69
- LIPO 36.24
- Support Level
- AQB $0.65
- LIPO $2.02
- Resistance Level
- AQB $0.69
- LIPO $3.00
- Average True Range (ATR)
- AQB 0.04
- LIPO 0.28
- MACD
- AQB -0.01
- LIPO -0.13
- Stochastic Oscillator
- AQB 28.44
- LIPO 8.78
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.